Veracyte, Inc.
NASDAQ: VCYT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- CEO
- Marc Stapley
- Employees
- 755
- Headquarters
- South San Francisco, United States
- IPO year
- 2013
- Market cap
- $4.8B
- Website
- https://www.veracyte.com
Loading VCYT…
Loading profile data…Frequently asked questions about VCYT
What does Veracyte, Inc. (VCYT) do?
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for b...
Where does VCYT trade?
Veracyte, Inc. (VCYT) trades on the NASDAQ.
What sector is VCYT in?
Veracyte, Inc. (VCYT) operates in the Healthcare sector, specifically in the Medical - Diagnostics & Research industry.
Who is the CEO of Veracyte, Inc.?
Marc Stapley is the chief executive officer of Veracyte, Inc. (VCYT).
Where is Veracyte, Inc. headquartered?
Veracyte, Inc. is headquartered in United States.
Does VCYT pay a dividend?
Veracyte, Inc. (VCYT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did VCYT go public?
Veracyte, Inc. (VCYT) completed its initial public offering in 2013.